Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer.
about
Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancerFactors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression AnalysisFactors influencing adherence to cancer treatment in older adults with cancer: a systematic reviewThe impact of overweight and obesity on breast cancer: data from Switzerland, so far a country little affected by the current global obesity epidemicDepression as a predictor of adherence to adjuvant endocrine therapy (AET) in women with breast cancer: a systematic review and meta-analysisOral antineoplastic agents: how do we care about adherence?Predicting Adherence to Aromatase Inhibitor Therapy among Breast Cancer Survivors: An Application of the Protection Motivation Theory."Winging It": How Older Breast Cancer Survivors Persist With Aromatase Inhibitor Treatment.A hard pill to swallow: a qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer.A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL).Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancerA nation-wide multicenter 10-year (1999-2008) retrospective clinical study of endocrine therapy for Chinese females with breast cancer.Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901.Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancerA population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patientsFactors associated to persistence with hormonal therapy in women with breast cancer.Adherence evaluation of endocrine treatment in breast cancer: methodological aspects.Perspectives on adherence and persistence with oral medications for cancer treatment.The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer.Assessing the efficacy of targeted therapy using circulating epithelial tumor cells (CETC): the example of SERM therapy monitoring as a unique tool to individualize therapy.Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment--the COMPAS study.Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer.Patient adherence to aromatase inhibitor treatment in the adjuvant setting.Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer.Exemestane in the adjuvant treatment of breast cancer in postmenopausal women.Characteristics of the Delayed or Refusal Therapy in Breast Cancer Patients: A Longitudinal Population-Based Study in Taiwan.Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysisAre Australian clinicians monitoring medication adherence in hematological cancer survivors? Two cross-sectional studies.Perspectives of postmenopausal breast cancer survivors on adjuvant endocrine therapy-related symptoms.Breast cancer treatment of older women in integrated health care settings.Understanding Statin Non-Adherence: Knowing Which Perceptions and Experiences Matter to Different Patients.Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income womenRacial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer.Nomogram to predict the benefit of radiation for older patients with breast cancer treated with conservative surgery.Endocrine therapy initiation from 2001 to 2008 varies by age at breast cancer diagnosis and tumor size.Noninitiation of adjuvant chemotherapy in women with localized breast cancer: the breast cancer quality of care studyPersistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907)The Breast Cancer Quality of Care Study (BQUAL): a multi-center study to determine causes for noncompliance with breast cancer adjuvant therapy.Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication
P2860
Q24632347-1EB050EF-1AF8-455D-A29A-D3B9F873C992Q26779595-C173A7A1-6638-460A-B639-94C090AB26BAQ26850736-67B9DCF6-9628-4E93-95AB-E12957660800Q27021293-E94CED32-C906-429D-B41F-3CA7AE14DC56Q27023110-327E81AF-6D42-431B-A4C3-6A330E7E5C5EQ28082909-5D0B677B-5D7B-4C6D-87EB-3C21730597F0Q33562869-78F953C6-541D-4A8B-9E2C-1A8E8DF0D72EQ33756757-576A2001-3570-4290-B9F4-0EFD527DD449Q33795923-28F4F008-4283-45BC-9D58-459386ACC325Q33857602-E1BCBF16-AFF4-4BF3-8507-0BDEDB7EEAC4Q33874887-397ABF68-79AD-47DD-B584-EB6C87490E1EQ33921197-0A8B661C-C65A-425D-BF17-13618ED6A63FQ33927985-87E268A8-518C-4366-87B4-FF87F303F405Q33965106-F478F792-7DDE-4CFD-86F6-5C459F3F3EDAQ33996270-6E9DF695-34A0-4FFC-8FF1-E32CC5A061C3Q34193946-DAECAF0E-DCE5-410F-A80D-B9935A0B618DQ34386558-B36AE88A-FC64-4C4F-80F3-7DED3C542EA8Q34445764-FA0662B3-89F5-44D6-8BA6-F6E9DF83C235Q34459748-197B6D1B-1548-4B85-BDA1-421BD6249566Q34736154-D1374838-F44C-48A6-A623-61B27D1D2C10Q34779138-75757BD5-4ECE-4F2E-BE02-B8B480BAF287Q34978630-7675949B-A16C-47DA-9A84-DE2CC8F31A8CQ35006809-22BE84E7-9D02-419E-AAE0-5DBAD96E1D06Q35059403-4DB10D01-9F77-44EC-BA1E-373A159E37B2Q35168777-554E9441-FC1B-49FE-A4AE-FA5370C9836DQ35440357-186D44DB-5F37-48D6-BFD0-473D4ED1A3D8Q35675550-1FE34A0F-560F-4C00-B0BF-A5F091430E6DQ35705287-84BE8952-1AD4-4A68-9A00-24ABB6066B15Q35747603-F6292CB7-78B0-47B1-8ECD-09EE131DACE2Q35845258-016A0DA3-606C-4111-9A1A-A95996471FE6Q35879504-6180445E-FEB8-4E3A-8A9B-A0B63C6AABBFQ35903382-B148368A-F5C0-4941-B6D4-A7EFCB94DA4FQ35968741-5AA1A198-2B62-4B60-8052-1CBA11CB32C7Q36033062-32501F8B-2CA4-40D2-AC56-A6685E12DD14Q36135193-FB3058AA-4A92-4F82-86A7-B9012B859AF1Q36278395-0E18DBCE-D075-4B87-941C-B8C1DB720982Q36339703-1DAC7241-472A-4195-A797-4D73BF3EE7C1Q36408545-972FC48F-5AC0-4BAD-AD42-9ED11B3FAC9DQ36459112-80943526-56AB-4A90-A7EA-D1EC51D62B18Q36556940-97FFFB92-D298-4DD9-A4B2-AA4DB55DCEFC
P2860
Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Patient beliefs and tamoxifen ...... eptor--positive breast cancer.
@en
Patient beliefs and tamoxifen ...... eptor--positive breast cancer.
@nl
type
label
Patient beliefs and tamoxifen ...... eptor--positive breast cancer.
@en
Patient beliefs and tamoxifen ...... eptor--positive breast cancer.
@nl
prefLabel
Patient beliefs and tamoxifen ...... eptor--positive breast cancer.
@en
Patient beliefs and tamoxifen ...... eptor--positive breast cancer.
@nl
P2093
P356
P1476
Patient beliefs and tamoxifen ...... ceptor--positive breast cancer
@en
P2093
Aliza K Fink
Edward Guadagnoli
Jerry Gurwitz
William Rakowski
P304
P356
10.1200/JCO.2004.11.064
P407
P577
2004-08-01T00:00:00Z